Dopamine is a neurotransmitter that has been implicated in processes as diverse as reward, addiction, control of coordinated movement, metabolism and hormonal secretion. Correspondingly, dysregulation of the dopaminergic system has been implicated in diseases such as schizophrenia, Parkinson's disease, depression, attention deficit hyperactivity disorder, and nausea and vomiting. The actions of dopamine are mediated by a family of five G-proteincoupled receptors 1 . The D2 dopamine receptor (DRD2) is the primary target for both typical 2 and atypical 3,4 antipsychotic drugs, and for drugs used to treat Parkinson's disease. Unfortunately, many drugs that target DRD2 cause serious and potentially lifethreatening side effects due to promiscuous activities against related receptors 4,5 . Accordingly, a molecular understanding of the structure and function of DRD2 could provide a template for the design of safer and more effective medications. Here we report the crystal structure of DRD2 in complex with the widely prescribed atypical antipsychotic drug risperidone. The DRD2-risperidone structure reveals an unexpected mode of antipsychotic drug binding to dopamine receptors, and highlights structural determinants that are essential for the actions of risperidone and related drugs at DRD2.
DRD2 has also been implicated in the actions of several drugs of abuse including amphetamines, cocaine and opioids 9 . Although DRD2 was cloned nearly 30 years ago [10] [11] [12] and has been subject to extensive pharmacological 13 , mutagenesis 14 and molecular-modelling studies 15 , we lack high resolution structures of DRD2 in complex with ligands, limiting our molecular understanding of its function. A 3.2 Å crystal structure of the related D3 dopamine receptor (DRD3) 16 and 1.95 Å and 2.2 Å structures of the D4 dopamine receptor (DRD4) have been reported 17 . The DRD3 and DRD4 ligand complexes-obtained with the substituted benzamides eticlopride and nemonapride, respectivelyrevealed distinctive extended binding sites 16, 17 . Given the importance of DRD2-targeted drugs, and recent successes in using structures of G-protein-coupled receptors (GPCRs) to guide discovery of new chemical probes and therapeutic leads 18, 19 , the structure of DRD2 complexed with non-benzamide ligands will not only clarify the specificity determinants of the family, but will also expand our understanding of how different scaffolds interact with dopamine receptors. We anticipate that the ligand discovery enabled by DRD2 structures will therefore inform both basic and translational neuroscience 20 .
We carried out structural studies using a human DRD2 construct, which included three thermostabilizing mutations (I122 3. 40 A, L375 6.37 A and L379 6.41 A; superscript refers to the Ballesteros-Weinstein numbering system for GPCRs 7 ) and T4 lysozyme (T4L) fused into intracellular loop 3 (Extended Data Fig. 1a, b and Methods). DRD2-risperidone structure ( Fig. 1c and Extended Data Fig. 2c ), and unlike the analogous residues in some aminergic receptor structures, Ile184 does not directly interact with the ligand (Extended Data Fig. 2a -l). Instead, Ile184 points across the binding pocket to interact with Trp100 in EL1, forming a hydrophobic network near the opening of the binding pocket (Extended Data Fig. 2m ). We note that interactions between T4L and EL1 and EL2 in the crystal lattice may further stabilize this conformation (Extended Data Fig. 1c-e ), but these weak interactions are unlikely to induce it. DRD2 also differs from the other two D2-like dopamine receptors in that the extracellular tip of TMV is shifted towards the transmembrane bundle, while the extracellular tips of TMVI and TMVII are approximately 5.8 and 7.3 Å, and 1.4 and 2.1 Å further away from the receptor core, respectively, in comparison to the same regions in DRD3 and DRD4 ( Fig. 1b ). As in DRD3, an inter-helical hydrogen bond forms between Tyr 7.35 and His 6.55 (Extended Data Fig. 3a-d) , which in DRD3 is important for regulating constitutive activity 17 . The side-chain conformations of DRD2, DRD3 16 Like most antipsychotics, risperidone is a DRD2 inverse agonist 22 , and therefore the DRD2-risperidone complex reflects an inactive state conformation. The most notable difference between active-and inactive-state GPCR structures is the extent to which the cytoplasmic tip of TMVI moves away from the transmembrane helical bundle to accommodate transducer binding 23 . A comparison of DRD2risperidone with the active and inactive β 2 adrenergic receptor (β2AR) or adenosine A 2A receptor (A2AR) structures reveals no substantial outward movement of the intracellular end of TMVI (Extended Data Fig. 3e , f), a finding consistent with an inactive-state structure. Another important structural feature of GPCR activation is the rearrangement of side chains in the highly conserved microswitches D(E)/RY (TMIII) and NPXXY (TMVII) 23 . Here, Tyr 7.53 from the NPXXY motif and Arg 3.50 from the DRY motif adopt almost identical positions with homologous residues in the β2AR and A2AR inactive structures (Extended Data Fig. 3g -j). Moreover, a key inactive-state saltbridge interaction, the 'ionic lock' between the conserved Arg 3.50 and Glu 6.30 (refs 24-26) is maintained in the DRD2-risperidone structure (Fig. 1d ).
The benzisoxazole risperidone 27 displays a unique mode of dopamine receptor binding in comparison to those of the substituted benzamides eticlopride to DRD3 and nemonapride to DRD4 (Fig. 2) . The benzisoxazole moiety of risperidone extends into a deep binding pocket defined by the side chains of TMIII, TMV and TMVI ( Fig. 2a,  d ), and interacts with Cys118 3.36 , Thr119 3.37 , Ser197 5.46 , Phe198 5.47 , Phe382 6.44 , Phe390 6.52 and Trp386 6.48 , which form a subpocket below the orthosteric site ( Fig. 2d ). Additionally, another hydrophobic pocket above the orthosteric site encloses the tetrahydropyridopyrimidinone moiety of risperidone, whereas Asp114 3.32 forms a salt bridge with the tertiary amine of risperidone ( Fig. 2d ). Alanine mutagenesis of many of these contact residues reduces the affinity of risperidone binding to DRD2 ( Fig. 2d and Extended Data Table 3 ). In the DRD3 and DRD4 structures, neither eticlopride nor nemonapride engages this deeper hydrophobic pocket (Fig. 2b, c) . Importantly, alanine substitutions of the equivalent residues in this deeper hydrophobic pocket do not substantially alter [ 3 H]-nemonapride binding affinity for the DRD3 and the DRD4 receptors, except for Trp386 6.48 and Phe390 6.52 , which are large enough that mutagenesis-induced alterations in helical packing alone might explain the observed effects (Extended Data Table 3 ).
Comparison of the overall ligand-binding pocket of DRD2 with structures of DRD3 and DRD4 revealed marked differences around residues Val/Phe 2.61 , Trp EL1 , Phe/Leu 3.28 and Tyr/Val 7.35 , which help to define an extended binding pocket (EBP) in DRD2 ( Fig. 3a, b) . Indeed, previous studies 16,17 on DRD3 and DRD4 revealed a selective EBP in each receptor. The DRD3 EBP is formed by the junction of EL1 and EL2 and the interface of TMII, TMIII and TMVII, and extends towards EL1 ( Fig. 3c ). By contrast, the DRD4 EBP reaches deep into a cleft between TMII and TMIII, defined by Phe91 2.61 and Leu111 3.28 (Fig. 3d) ; the structural determination of this DRD4 EBP enabled the structure-based discovery of agonists that are highly specific for this receptor 17 . Unlike DRD3 or DRD4, the DRD2 EBP extends towards the extracellular part of TMVII, and is formed by EL1 and the junction of TMI, TMII and TMVII ( Fig. 3b ).
There are four distinctive features of the DRD2 EBP: (1) Compared to the DRD3 structure, part of the EL1 loop is rotated in DRD2, moving the conserved residue Trp EL1 to the top of the binding pocket ( (2) The phenylalanine residue is located at 3.28 in DRD2, rather than 2.61 in DRD4, which eliminates the equivalent of the extended pocket of DRD4 in DRD2 ( Fig. 3a , b, d). (3) The Tyr408 7.35 side chain rotates towards the His393 6.55 side chain in DRD2, thereby avoiding clashing with risperidone (Extended Data Fig. 3a, d ). (4) Finally, an outward movement of the extracellular tip of TMVII ( Fig. 1b ) makes additional space for the DRD2 EBP.
In comparison with the conformation adopted by risperidone when crystallized in isolation 4 ring rotates by around 90° in the complex with DRD2 (Extended Data Fig. 5a ). This ring interacts with a hydrophobic patch formed by the side chains of Trp100 EL1 , Ile184 EL2 , and Leu94 2.64 . Although the electron density for Leu94 2.64 is weaker than for the other residues, the observed conformation of Trp100 EL1 appears to be stabilized by any rotamer of Leu94 2.64 that would fit the density.
In the DRD2-risperidone structure, the side chain of Trp100 EL1 forms extensive contacts with the tetrahydropyridopyrimidinone ring, wedging it into the DRD2 EBP (Figs. 3b, 4a and Extended Data Fig. 5b ). In addition to these hydrophobic contacts between Trp100 EL1 and risperidone, Trp100 EL1 is also stabilized by contacts with Ile184 EL2 and, perhaps, Leu94 2.64 , in spite of the lack of side chain electron density ( Fig. 4b and Extended Data Fig. 5c ). The observed configuration of risperidone is likely to be driven by the binding pocket of DRD2, and the conservation of key pocket residues such as Trp100 EL1 implies that risperidone could bind other aminergic receptors (for example, 5HT2A or the α1A adrenergic receptor) in a similar conformation, although further structures will be needed to test this notion.
Molecular docking of risperidone to homology models of DRD2, based on either the DRD3 or DRD4 structures, failed to reproduce the unique pose adopted by risperidone in the complex (Extended Data Fig. 5d -h). Rather, docking placed the ligand higher in the binding site, in a location analogous to that of eticlopride and nemonapride in the DRD3 and DRD4 structures, respectively (Fig. 2b, c ). This is a direct consequence of the conformational rearrangements in DRD2 concomitant with accommodating risperidone-mainly movement of TMV, TMVI and TMVII, and the relocation of Trp100 EL1 , which consequently affects the size and shape of the ligand-binding pocket, allowing risperidone to engage a deep binding pose and enter DRD2 EBP. Moreover, the docked conformation of risperidone resembles that of the receptor-free risperidone crystal structure 4 , rather than the conformation adopted in the receptor-bound complex (Extended Data Fig. 5d -h). This is not a problem of conformational sampling on the part of docking-the receptor-free structure is, after all, a low energy structure, and docking captures this-but rather, it reflects the incorrect modelling of Trp100 EL1 , owing to the lack of an analogous configuration in templates used in the modelling. Accordingly, docking does not predict the approximately 90° rotation of the tetrahydropyridopyrimidinone ring of risperidone in the DRD2 complex. The binding pocket of DRD2 and the unusual risperidone conformation that it accommodates are unexpected features of this structure, with implications for our understanding of ligand recognition by this receptor and for the design of new ligands to modulate its activity.
The rearrangement of the extracellular surface and movement of Trp100 EL1 in comparison to the DRD3 and DRD4 structures not only allows it to interact with risperidone, but also forms, together with Ile184 EL2 and Leu94 2.64 , a hydrophobic patch that potentially narrows the binding pocket (Fig. 4b, c ). We hypothesized that these residues prevent risperidone from exiting the binding pocket. We found that Trp100 EL1 Phe, Trp100 EL1 Leu and Trp100 EL1 Ala mutations decreased risperidone residence time from 233 min in the wild-type receptor to 59, 23 and 28 min, respectively ( Table 1 and Extended Data Fig.  6a-d) . Notably, these kinetic effects of the Trp100 EL1 Phe, Trp100 EL1 Leu and Trp100 EL1 Ala mutants on residence time were shared with other tested antipsychotics, including N-methylspiperone, nemonapride and aripiprazole (Extended Data Fig. 6h -k, o-p and Extended Data Table 4 ). Similarly, the I184 ECL2 A/L94 2.64 A double mutation (Table 1 and Extended Data Fig. 6g ) reduced the residence time of risperidone to 6 min, and also reduced the residence times of other antipsychotics ( Table 1 , Extended Data Fig. 6n , q, r and Extended Data Table 4 ). In summary, L94 2.64 , Trp100 EL1 and I184 ECL2 form hydrophobic contacts that contribute to the slow dissociation of risperidone from DRD2.
Among the most serious side effects of antipsychotics are extrapyramidal symptoms (EPS). A consistent finding in patients with EPS is DRD2 occupancy of more than 80% in the central nervous system, as demonstrated by positron emission tomography (PET) 28 . It has been hypothesized that differential binding kinetics 29,30 and the relatively higher affinity of atypical antipsychotic drugs for 5HT2A serotonin receptors 3, 4 contribute to the lower incidence of EPS with atypical antipsychotic drugs, such as risperidone, versus typical antipsychotics. We note that Trp100 EL1 regulates both the association and dissociation kinetics of risperidone, and that many of the residues that are essential for risperidone binding to DRD2 are shared with 5HT2A serotonin and other biogenic amine receptors. Thus, although our findings do not definitively resolve these hypotheses, they do provide the initial underpinnings for molecularly derived models of the actions of antipsychotic drugs at dopamine and other receptors. Finally, given recent successes in leveraging crystal structures of GPCRs for ligand discovery [17] [18] [19] , we anticipate that the DRD2-risperidone complex structure will accelerate the search for novel antipsychotic drugs targeting DRD2. 
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Protein engineering for structural studies. To facilitate expression, purification, and crystallography, a human DRD2 (D2 long receptor variant 12 ) construct was generated with several modifications. T4L residues 2-161 31 were fused into the third intracellular loop of DRD2 (V223-R361) with truncations of the N-terminal residues 1-34. The DRD2-T4L construct was further modified by introducing three mutations I122 3.40 A, L375 6.37 A and L379 6.41 A, identified by alanine scanning, to improve protein thermostability. In brief, alanine scanning was used to identify thermostabilization mutations (see 'Radioligand binding assay' for details; Extended Data Fig. 1a ). The chimeric receptor sequences were then subcloned into a modified pFastBac1 vector (Invitrogen), designated pFastBac1-833100, which contained an expression cassette with a haemagglutinin signal sequence followed by a Flag tag, a 10×His tag and a TEV protease recognition site at the N terminus before the receptor sequence. Protein expression and purification. The modified DRD2-T4L protein was expressed in Spodoptera frugiperda (Sf9) cells (Expression Systems) using the Bac-to-Bac Baculovirus Expression System (Invitrogen) for 48 h. The insect cells were lysed by repeated washing and centrifugation in hypotonic buffer with low (10 mM HEPES, pH 7.5, 10 mM MgCl 2 , 20 mM KCl and EDTA-free complete protease inhibitor cocktail tablets (Roche)) (once) and high (1.0 M NaCl, 10 mM HEPES, pH 7.5, 10 mM MgCl 2 , 20 mM KCl) salt concentration (three times). The washed membranes were suspended in buffer containing 10 mM HEPES, pH 7.5, 10 mM MgCl 2 , 20 mM KCl, 150 mM NaCl, 20 μM risperidone and EDTA-free complete protease inhibitor cocktail tablets, incubated at room temperature for 1 h and then incubated at 4 °C for 30 min before solubilization. The membranes were then solubilized in 10 mM HEPES, pH 7.5, 150 mM NaCl, 1% (wt/vol) n-dodecyl-β-D-maltopyranoside (DDM, Anatrace), 0.2% (wt/vol) cholesteryl hemisuccinate (CHS, Sigma) for 2 h at 4 °C.
The supernatant was isolated by centrifugation at 150,000 g for 30 min, followed by incubation in 20 mM buffered imidazole (pH 7.5) and 800 mM NaCl with TALON IMAC resin (Clontech) at 4 °C overnight. The resin was then washed with 10 column volumes of Wash Buffer I (50 mM HEPES, pH 7.5, 800 mM NaCl, 0.1% (wt/vol) DDM, 0.02% (wt/vol) CHS, 20 mM imidazole, 10% (vol/vol) glycerol and 10 μM risperdone), followed by 10 column volumes of Wash Buffer II (25 mM HEPES, pH 7.5, 150 mM NaCl, 0.05% (wt/vol) DDM, 0.01% (wt/vol) CHS, 10% (vol/vol) glycerol and 10 μM risperidone). The protein was then eluted in 3-4 column volumes of Elution Buffer (50 mM HEPES (pH 7.5), 50 μM risperidone, 500 mM NaCl, 10% (vol/vol) glycerol, 0.05% (wt/vol) DDM, 0.01% (wt/vol) CHS, and 250 mM imidazole). A PD MiniTrap G-25 column (GE Healthcare) was used to remove imidazole. The protein was then treated overnight with His-tagged TEV protease and His-tagged PNGase F (NEB) to remove the N-terminal His tag and Flag-tag, and to deglycosylate the receptor. His-tagged TEV protease, His-tagged PNGase F, cleaved His-tag and uncleaved protein were removed from the sample by passing the sample over equilibrated TALON IMAC resin (Clontech). The receptor was then concentrated to 40-50 mg ml −1 with a 100 kDa molecular mass cut-off Vivaspin 500 centrifuge concentrator (Sartorius Stedim). Lipidic cubic-phase crystallization. Protein samples of DRD2 in complex with risperidone were reconstituted into the lipidic cubic phase (LCP) by mixing 40% of ~60 mg ml −1 purified DRD2-risperidone with 60% lipid (10% (wt/wt) cholesterol, 90% (wt/wt) monoolein) using the twin-syringe method 32 . Crystallization trials were performed in glass sandwich plates (Marienfeld) using a handheld dispenser (Art Robbins Instruments), dispensing 50 nl of protein-laden LCP and 1 μl precipitant solution per well. Plates were then incubated at 20 °C. Crystals were obtained from precipitant conditions containing 100 mM Tris/HCl pH 7.8, 230 mM lithium nitrate, 25% PEG400, 4% (±)1,3-butanediol. Crystals grew to maximum size of 40 μm × 40 μm × 10 μm within two weeks and were harvested directly from the LCP matrix using MiTeGen micromount loops and flash frozen in liquid nitrogen. Data collection, structure solution and refinement. Crystallographic diffraction data collection was performed at the 23ID-B and 23ID-D beamlines (GM/CA CAT) at the Advanced Photon Source, Argonne, Illinois using a 10-μm minibeam at a wavelength of 1.0330 Å and a Dectris Eiger-16m or Pilatus3 6M detector, respectively. The crystals were exposed to 0.5 s of unattenuated beam using 0.5° oscillation per frame. A 97.3% complete data set at 2.90 Å resolution of DRD2risperidone from 20 crystals was integrated, scaled and merged using HKL3000 33 . Initial phase information was obtained by molecular replacement with the program PHASER 34 using two independent search models: a receptor portion of the DRD4nemonapride complex (PDB code: 5WIU), and the T4L portion of β2AR-T4L (PDB code: 2RH1) as initial models. Refinement was performed with PHENIX 35 and REFMAC followed by manual examination and rebuilding of the refined coordinates in the program COOT 36 using |2F o |−|F c |, |F o |−|F c |, and omit maps. Radioligand-binding assay. Binding assays were performed using membrane fractions of Sf9 cells expressing the crystallization construct DRD2-T4L (I122 3.40 A, L375 6.37 A and L379 6.41 A) or membrane preparations of HEK-293T transiently expressing DRD2 (D2 long receptor) and different mutants. HEK-293T cells (ATCC CRL-11268; 59587035; mycoplasma free) were transfected and membrane preparation and radioligand binding assays were set up in 96-well plates as described previously 13 . All binding assays were conducted in standard binding buffer (50 mM Tris, 10 mM MgCl 2 , 0.1 mM EDTA, 0.1% BSA, pH 7.4). For displacement experiments, increasing concentrations of compounds were incubated with membrane and radioligands (0.8-1.0 nM [ 3 H]-N-methylspiperone or 0.1-0.5 nM [ 3 H]-nemonapride) (PerkinElmer) for 2 h at room temperature in the dark. To determine the affinity of nemonapride for DRD2 and different mutants, all assays used at least two concentrations of [ 3 H]-nemonapride. The reaction was terminated by rapid vacuum filtration onto chilled 0.3% PEI-soaked GF/A filters followed by three quick washes with cold washing buffer (50 mM Tris HCl, pH 7.4) and quantified as described previously 8 . Results (with or without normalization) were analysed using GraphPad Prism using one-site shift models where indicated. Radioligand-based thermostability assay. Membranes from HEK-293T cells expressing wild-type or mutant human DRD2 were resuspended in binding buffer (50 mM Tris, 10 mM MgCl 2 , 0.1 mM EDTA, 0.1% BSA, pH 7.4). [ 3 H]-Nmethylspiperone was added to the membranes to give a final concentration of 1 nM. The samples were incubated at room temperature for 1 h and then aliquoted into PCR strips. Samples were heated to the desired temperature for exactly 30 min, then cooled down to 25 °C for 30 min. The samples were terminated by rapid vacuum filtration onto chilled 0.3% PEI-soaked GF/A filters followed by three quick washes with cold washing buffer (50 mM Tris HCl, pH 7.4) and quantified as described previously 8 . Results were analysed using GraphPad Prism. Apparent T m values were derived from sigmoidal dose-response analysis. Results represent the mean ± s.e.m. of three independent experiments. Differential-scanning fluorimetry-based thermostability assay. The thermal stability of purified protein was determined by measuring fluorescence of the thiol-reactive dye BODIPY FL l-cystine (Invitrogen). The standard assay conditions were 20 mM HEPES (pH 7.5), 200 mM NaCl, 0.025% DDM and 10 mM risperidone with protein concentrations of 1 mg ml −1 and 1 μM BODIPY FL l-cystine. The melting experiments were performed on a StepOnePlus real-time PCR system from Applied Biosystems. The melting curve experiments were conducted (1 °C/ min) and recorded using StepOne software from Applied Biosystems. Results were analysed using GraphPad Prism. Apparent T m values were derived from sigmoidal dose-response analysis. Results represent the mean ± s.e.m. of three independent experiments. Ligand association and dissociation radioligand-binding assays. Binding assays were performed using membrane preparations of HEK-293T cells transiently expressing DRD2 (D2 long receptor) and different mutants at room temperature. Radioligand dissociation and association assays were performed in parallel using the same concentrations of radioligand, membrane preparations and binding buffer (50 mM Tris, 10 mM MgCl 2 , 0.1 mM EDTA, 0.1% BSA, pH 7.4). All assays used at least two concentrations of radioligand (0.5-1.0 nM [ 3 H]-N-methylspiperone; 0.5-2.0 nM [ 3 H]-nemonapride). For dissociation assays, membranes were incubated with radioligand for at least 2 h at room temperature before the addition of 10 μl of 10 μM excess cold ligand to the 200 μl membrane suspension at designated time points. For association experiments, 100 μl of radioligand was added to 100 μl membrane suspensions at designated time points. Time points spanned 1 min to 7 h, depending on experimental conditions and radioligand. For the determination of k on and k off for unlabelled risperidone or aripiprazole, membranes containing either wild-type or mutant proteins were incubated with [ 3 H]-methylspiperone and several concentrations of risperidone or aripiprazole. Non-specific binding was determined by addition of 10 μM nemonapride. Immediately (at time = 0 min), plates were harvested by vacuum filtration onto 0.3% polyethyleneimine pre-soaked 96-well filter mats (Perkin Elmer) using a 96-well Filtermate harvester, followed by three washes with cold wash buffer (50 mM Tris pH 7.4). Scintillation cocktail (Meltilex, Perkin Elmer) was melted onto dried filters and radioactivity was counted using a Wallac Trilux MicroBeta counter (PerkinElmer). Data were analysed using 'dissociation-one phase exponential decay' or 'association kinetics-two or more concentrations of hot radioligand' in Graphpad Prism 5.0. The previously determined [ 3 H]-Nmethylspiperone k on and k off rates of DRD2 or mutants were used to estimate the k on and k off rates of risperidone and aripiprazole using the 'kinetics of competitive binding' equation in Graphpad Prism 5.0 as proposed 37 . Homology modelling of DRD2. Sequence alignment for construction of the DRD2 homology models was generated with PROMALS3D 38 , using sequences of human DRD2 (Uniprot accession number: P14416), DRD3 (P35462) and DRD4 (P21917), as well as sequences of available DRD2-family X-ray structures (DRD3, PDB code: 3PBL (chain A) 16 and DRD4, PDB code: 5WIU (chain A) 17 ). The 
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Experimental design 1. Sample size
Describe how sample size was determined.
No statistical methods were used to predetermine sample sizes. Due to radiation damage, X-ray diffraction data collection of the protein crystals was limited to 5-10 degree per crystal. To collect a complete data set for structure determination, diffraction data from multiple crystals were integrated and scaled using HKL2000. By calculating completeness of the data set, diffraction data from 20 crystals were used to ensure the completeness was close to 100%.
Data exclusions
Describe any data exclusions.
No data were excluded.
Replication
Describe the measures taken to verify the reproducibility of the experimental findings.
All attempts at replication were successful.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
Randomization is not relevant to this study, as protein and crystal samples are not required to be allocated into experimental groups in protein structural studies, and no animals or human research participants are involved in this study.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
Blinding is not relevant to this study, as protein and crystal samples are not required to be allocated into experimental groups in protein structural studies, and no animals or human research participants are involved in this study. Note: all in vivo studies must report how sample size was determined and whether blinding and randomization were used.
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Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed). n/a Confirmed The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section. For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for providing algorithms and software for publication provides further information on this topic.
